AFT signs North American licensing deal for Pascomer topical treatment

AFT signs North American licensing deal for Pascomer topical treatment
Paul McBeth
By Paul McBeth July 5 (BusinessDesk) - AFT Pharmaceuticals is eyeing a US$10 million payment from a North America licensing deal but is keeping its earnings guidance unchanged for now.  The maker of Maxigesic painkillers reached the licensing and development agreement with US-based Timber Pharmaceuticals for its Pascomer drug, which treats skin lesions known as facial angiofibromas associated with the genetic disorder, tuberous sclerosis.  Timber will cover the cost of two clinical trials involving 120 patients, with the results due ne...

More Services

Auckland accountancy snapped up by Hong Kong firm Acclime
Services

Auckland accountancy snapped up by Hong Kong firm Acclime

It is the second Auckland firm Acclime has acquired in as many years.

John Anthony 11 Apr 2025
Engineering firms lose 1200 people in a year
Services

Engineering firms lose 1200 people in a year

But despite the job numbers, most firms were optimistic about the sector’s prospects.

Staff reporters 09 Apr 2025
Former school lunch provider in liquidation
Law & Regulation

Former school lunch provider in liquidation

Secret Chef stopped trading in December last year.

Michael Neilson 18 Mar 2025
Libelle approached liquidators late last week
Services Exclusive

Libelle approached liquidators late last week

Liquidators were called on the same day a student was burned by a meal.

Cécile Meier 11 Mar 2025